The scientific objective of establishing an international network for identification, evaluation, and longitudinal follow-up of families with early onset dominantly inherited Alzheimer's disease (AD) is addressed in the overview of this renewal application and in Core B: Clinical. The activities of the Core C: Biostatistics are designed to enhance the research objectives of DIAN by serving the DIAN investigators with a smooth transition from the database to statistical analyses, providing appropriate statistical analysis resources to all Cores, and developing necessary longitudinal statistical models to test the preclinical hypotheses of DIAN on all major biomarkers of AD. The major hypotheses in DIAN conjecture a period of preclinical AD in individuals who are destined to develop early onset dementia (mutation carriers) that can be detected by changes in biological fluids and in neuroimaging correlates in comparison with individuals who will not develop early onset dementia (noncarriers) and a temporal difference in preclinical changes across these correlates for mutation carriers. The methodological significance of the hypothesis is the requirement of state-of-the-art longitudinal statistical models to adequately estimate and compare the longitudinal rates of change on multi-modal disease markers during the preclinical period, and to assess their association with the risk of subsequent development of symptomatic AD.
In the proposed DIAN renewal, Core C: Biostatistics Core will bridge the transition from the DIAN database stored and managed by Core H: Informatics Core to the analyses of the longitudinal as well as cross-sectional data. Specifically, the Biostatistics Core will oversee the statistical quality control of data and appropriate data analyses for the study by producing appropriately de-identified and statistically analyzable datasets for distribution/analysis and leading the statistical data analyses for all Cores.
|Bateman, Randall J; Benzinger, Tammie L; Berry, Scott et al. (2016) The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement :|
|Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0163669|
|Soosman, Steffan K; Joseph-Mathurin, Nelly; Braskie, Meredith N et al. (2016) Widespread white matter and conduction defects in PSEN1-related spastic paraparesis. Neurobiol Aging 47:201-209|
|Lim, Yen Ying; Hassenstab, Jason; Cruchaga, Carlos et al. (2016) BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain 139:2766-2777|
|Miller-Thomas, Michelle M; Sipe, Adam L; Benzinger, Tammie L S et al. (2016) Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics 36:1147-63|
|Muenchhoff, Julia; Poljak, Anne; Thalamuthu, Anbupalam et al. (2016) Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. Sci Rep 6:29078|
|Tang, Mengxuan; Ryman, Davis C; McDade, Eric et al. (2016) Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol 15:1317-1325|
|Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0152082|
|Jin, Yan; Su, Yi; Zhou, Xiao-Hua et al. (2016) Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network. EURASIP J Bioinform Syst Biol 2016:12|
|Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2016) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord :|
Showing the most recent 10 out of 29 publications